Abu dhabi: M42 and Arcera Life Sciences have signed a Memorandum of Understanding (MoU) to formalise a strategic collaboration aimed at advancing biopharma localisation, clinical development, and next-generation healthcare innovation in Abu Dhabi. The partnership is aligned with the Department of Health - Abu Dhabi's efforts to position the Emirate as a global hub for life sciences innovation.
According to Emirates News Agency, the collaboration between M42 and Arcera seeks to develop an integrated life sciences ecosystem that spans clinical development and innovative therapeutics. This initiative will focus on addressing genetic and rare diseases with scalable treatments. Arcera will collaborate with M42 to leverage genomics data, assessing disease prevalence across specific genetic and rare diseases.
The collaboration combines genomics insights supported by the Department of Health with M42's data platforms and healthcare delivery capabilities, alongside Arcera's expertise in late-stage drug development, business development, and market access. This collective effort aims to accelerate the introduction of innovative therapies and improve patient access to advanced treatment solutions in the region.
The collaboration is structured around four strategic pillars. The first pillar focuses on genomics-informed therapeutic development, leveraging genomic insights generated through national health and research programmes, alongside M42's data platforms and Arcera's late-stage development expertise to advance precision medicine and next-generation therapies, including cell and gene therapies.
The second pillar aims to accelerate clinical development by supporting late-phase clinical trials, strengthening evidence generation, and expanding patient access to innovative treatments. The third pillar involves advanced biobanking and the development of stem cell therapies and regenerative medicine. This will draw on capabilities like Abu Dhabi Biobank to enable breakthrough therapeutic innovation.
The final pillar targets digital and AI-enabled transformation, embedding innovative technologies across the life sciences value chain to enhance development efficiency and reinforce Abu Dhabi's leadership in AI-driven healthcare. These pillars are designed to support both immediate collaboration opportunities and long-term capability building across Abu Dhabi's health and life sciences ecosystem.
Through this collaboration, M42 and Arcera will establish a framework for evaluating joint opportunities, identifying priority use cases, and enabling collaboration across development and commercialisation. Dr. Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health, highlighted the role of the partnership in accelerating biopharma development and supporting future treatments for genetic and rare diseases.
Dr. Fahad Al Marzooqi, CEO of M42 Integrated Health Solutions, emphasized the strategic importance of the partnership in strengthening Abu Dhabi's life sciences ecosystem. Isabel Afonso, CEO of Arcera Life Sciences, noted that the collaboration reflects the strength of the national ecosystem, bringing together innovation, manufacturing, and patient access to deliver sustainable patient impact.